XM does not provide services to residents of the United States of America.
N
N

Novartis

News

China c.bank seen holding medium-term lending rate steady Monday

China c.bank seen holding medium-term lending rate steady Monday SHANGHAI/SINGAPORE, July 12 (Reuters) - China's central bank is widely expected to leave a medium-term interest rate unchanged and drain some cash from the banking system when rolling over such maturing loans on Monday, a Reuters survey showed. While the economy continues to sputter, a weak Chinese currency has remained the key constraint limiting Beijing's monetary easing efforts, as that could further widen the yield gap with oth
B
N

European companies cut jobs as economy sputters

FACTBOX-European companies cut jobs as economy sputters Adds details on fresh job cuts July 9 (Reuters) - Elevated levels of inflation and the impact of the war in Ukraine have forced companies across Europe to freeze hiring or cut jobs. Here are some layoffs announced since the start of April: BANKS * TSB: The British bank owned by Spain's Sabadell SABE.MC is seeking 250 job cuts and 36 branch closures, its spokesperson and employee union said on May 8. INDUSTRIALS AND ENGINEERING * METSO METSO
B
B
B
B
C
I
M
N
T
T
U
V
B
U

Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector

Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector COPENHAGEN, July 5 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO has been reprimanded by UK regulators for failing to disclose fees and expenses paid to individuals and organisations in Britain amounting to about 7.8 million pounds ($9.97 million) between 2020 and 2022. The UK industry body Prescription Medicines Code of Practice Authority (PMCPA) said on Friday that the reprimand followed a voluntary submi
N
P

Pearson, Softcat, Trelleborg

EUROPE RESEARCH ROUNDUP- Pearson, Softcat, Trelleborg July 5 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Pearson, Softcat and Trelleborg, on Friday. HIGHLIGHTS * Aker BP ASA AKRBP.OL : Jefferies cuts target price to NOK 340 from NOK 345 * GSK GSK.L : Citigroup cuts target price to 1900p from 2120p * Pearson PSON.L : Deutsche Bank raises target price to 1052p from 1050p * Softcat Plc SCTS.L : Jefferies cuts target price to 1,490p
A
A
B
C
C
D
D
E
E
G
I
K
N
N
P
T
T
T
V
W
A
D
Y

A closer look at U.S. drug pricing risks

LIVE MARKETS-A closer look at U.S. drug pricing risks STOXX 600 up 0.8% Paris, Milan bourses outperform Fed rate cut bets support mood Wall St futures broadly unchanged Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com A CLOSER LOOK AT U.S.
A
A
E
N
U
E
F
I
U
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.